Of note, a recently published study reported increased time in euglycemia and reduced time in hypoglycemia using a bihormonal SC FCL system modulating both insulin and glucagon compared with UC in 12 outpatients after total pancreatectomy.16 Future head-to-head comparative studies of insulin-only versus combined insulin/glucagon SC FCL systems will unravel whether the increased complexity of a dual hormone approach is justified in pancreatectomized patients. The gene discussed is INS; the disease is Hypoglycemia.